Chem Shift validation:  AVS_full
BMRB Entry DOI: doi:10.13018/BMR50461
            
                    NMR-STAR file interactive viewer.
                    NMR-STAR v3 text file.
                    XML gzip file.
                    RDF gzip file.
                    All files associated with the entry
                
Citation: Ogden, Tom; Yang, Ji-Chun; Schimpl, Marianne; Easton, Laura; Underwood, Elizabeth; Rawlins, Philip; McCauley, Michael; Langelier, Marie-France; Pascal, John; Embrey, Kevin; Neuhaus, David. "Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition"  Nucleic Acids Res. 49, 2266-2288 (2021).
PubMed: 33511412
Assembly members:
entity_1, polymer, 360 residues,  Formula weight is not available
Natural source: Common Name: Human Taxonomy ID: 9606 Superkingdom: Eukaryota Kingdom: Metazoa Genus/species: Homo sapiens
Experimental source: Production method: recombinant technology Host organism: Escherichia coli Vector: pET28
| Data type | Count | 
| 15N chemical shifts | 331 | 
| 1H chemical shifts | 331 | 
| T1 relaxation values | 313 | 
| T1rho relaxation values | 312 | 
| heteronuclear NOE values | 319 | 
| Entity Assembly ID | Entity Name | Entity ID | 
|---|---|---|
| 1 | PARP-1_CAT_domain L713F mutant | 1 | 
Entity 1, PARP-1_CAT_domain L713F mutant 360 residues - Formula weight is not available
The first residue in the sequence supplied here is a non-native glycine arising from cloning. The remaining residues are residues 656-1014 of human PARP-1 (the isoform having Ala at position 762), but with L765F mutation.
| 1 | GLY | THR | VAL | ASN | PRO | GLY | THR | LYS | SER | LYS | |
| 2 | LEU | PRO | LYS | PRO | VAL | GLN | ASP | LEU | ILE | LYS | |
| 3 | MET | ILE | PHE | ASP | VAL | GLU | SER | MET | LYS | LYS | |
| 4 | ALA | MET | VAL | GLU | TYR | GLU | ILE | ASP | LEU | GLN | |
| 5 | LYS | MET | PRO | LEU | GLY | LYS | LEU | SER | LYS | ARG | |
| 6 | GLN | ILE | GLN | ALA | ALA | TYR | SER | ILE | PHE | SER | |
| 7 | GLU | VAL | GLN | GLN | ALA | VAL | SER | GLN | GLY | SER | |
| 8 | SER | ASP | SER | GLN | ILE | LEU | ASP | LEU | SER | ASN | |
| 9 | ARG | PHE | TYR | THR | LEU | ILE | PRO | HIS | ASP | PHE | |
| 10 | GLY | MET | LYS | LYS | PRO | PRO | LEU | LEU | ASN | ASN | |
| 11 | ALA | ASP | SER | VAL | GLN | ALA | LYS | ALA | GLU | MET | |
| 12 | LEU | ASP | ASN | LEU | LEU | ASP | ILE | GLU | VAL | ALA | |
| 13 | TYR | SER | LEU | LEU | ARG | GLY | GLY | SER | ASP | ASP | |
| 14 | SER | SER | LYS | ASP | PRO | ILE | ASP | VAL | ASN | TYR | |
| 15 | GLU | LYS | LEU | LYS | THR | ASP | ILE | LYS | VAL | VAL | |
| 16 | ASP | ARG | ASP | SER | GLU | GLU | ALA | GLU | ILE | ILE | |
| 17 | ARG | LYS | TYR | VAL | LYS | ASN | THR | HIS | ALA | THR | |
| 18 | THR | HIS | ASN | ALA | TYR | ASP | LEU | GLU | VAL | ILE | |
| 19 | ASP | ILE | PHE | LYS | ILE | GLU | ARG | GLU | GLY | GLU | |
| 20 | CYS | GLN | ARG | TYR | LYS | PRO | PHE | LYS | GLN | LEU | |
| 21 | HIS | ASN | ARG | ARG | LEU | LEU | TRP | HIS | GLY | SER | |
| 22 | ARG | THR | THR | ASN | PHE | ALA | GLY | ILE | LEU | SER | |
| 23 | GLN | GLY | LEU | ARG | ILE | ALA | PRO | PRO | GLU | ALA | |
| 24 | PRO | VAL | THR | GLY | TYR | MET | PHE | GLY | LYS | GLY | |
| 25 | ILE | TYR | PHE | ALA | ASP | MET | VAL | SER | LYS | SER | |
| 26 | ALA | ASN | TYR | CYS | HIS | THR | SER | GLN | GLY | ASP | |
| 27 | PRO | ILE | GLY | LEU | ILE | LEU | LEU | GLY | GLU | VAL | |
| 28 | ALA | LEU | GLY | ASN | MET | TYR | GLU | LEU | LYS | HIS | |
| 29 | ALA | SER | HIS | ILE | SER | LYS | LEU | PRO | LYS | GLY | |
| 30 | LYS | HIS | SER | VAL | LYS | GLY | LEU | GLY | LYS | THR | |
| 31 | THR | PRO | ASP | PRO | SER | ALA | ASN | ILE | SER | LEU | |
| 32 | ASP | GLY | VAL | ASP | VAL | PRO | LEU | GLY | THR | GLY | |
| 33 | ILE | SER | SER | GLY | VAL | ASN | ASP | THR | SER | LEU | |
| 34 | LEU | TYR | ASN | GLU | TYR | ILE | VAL | TYR | ASP | ILE | |
| 35 | ALA | GLN | VAL | ASN | LEU | LYS | TYR | LEU | LEU | LYS | |
| 36 | LEU | LYS | PHE | ASN | PHE | LYS | THR | SER | LEU | TRP | 
sample_1: human PARP-1 CAT domain L713F mutant, [U-15N], 0.4 mM; TRIS, [U-2H], 50 mM; sodium chloride 50 mM; DTT, [U-2H], 2 mM
sample_conditions_1: ionic strength: 50 mM; pH: 7.0; pressure: 1 atm; temperature: 298 K
| Name | Sample | Sample state | Sample conditions | 
|---|---|---|---|
| 2D 1H-15N TROSY | sample_1 | isotropic | sample_conditions_1 | 
| 3D 15N-separated NOESY | sample_1 | isotropic | sample_conditions_1 | 
| 2D 1H-15N TROSY-based steady-state 15N{1H} NOE measurement | sample_1 | isotropic | sample_conditions_1 | 
| 2D 1H-15N TROSY-based 15N T1 measurement | sample_1 | isotropic | sample_conditions_1 | 
| 2D 1H-15N TROSY-based 15N T1rho measurement | sample_1 | isotropic | sample_conditions_1 | 
TOPSPIN v3.2 and 3.5 - processing
MddNMR v2.4 - processing
NMRPipe v8.7 - processing
ANALYSIS v2.4.2 - data analysis
SPARKY v3.115 - data analysis
Download HSQC peak lists in one of the following formats:
            
CSV: Backbone
            or all simulated peaks
            
SPARKY: Backbone
            or all simulated peaks